Aligos Therapeutics (ALGS) Return on Capital Employed (2020 - 2026)
Aligos Therapeutics' (ALGS) quarterly Return on Capital Employed came in at 179.75% in Q1 2026, down 8533.0% YoY from 2.13% in Q1 2025, and down 59.18% on a QoQ basis from 112.92% in Q4 2025.
Aligos Therapeutics (ALGS) Return on Capital Employed (2020 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 7 years of Return on Capital Employed data on file, last reported at 179.75% in Q1 2026.
- Quarterly Return on Capital Employed fell 8533.0% year-over-year to 179.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 179.75% (down 8533.0% YoY) and the FY2025 annual result came in at 151.49%, down 5140.0% from the prior year.
- Return on Capital Employed declined to 179.75% in Q1 2026, from 112.92% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 64.12% in Q2 2025 to a low of 179.75% in Q1 2026.
- A 5-year average of 98.97% and a median of 92.98% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed surged 4206 bps — and 2026, when it slumped 8533 bps.
- Tracing ALGS's Return on Capital Employed over 5 years: stood at 79.82% in 2022, then slipped by 16 bps to 92.98% in 2023, then plunged by 67 bps to 154.99% in 2024, then advanced by 27 bps to 112.92% in 2025, then plunged by 59 bps to 179.75% in 2026.
- The last three Return on Capital Employed figures came in at 179.75% (Q1 2026), 112.92% (Q4 2025), and 86.52% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 7.88% |
| 10 | Aligos Therapeutics | 69.57 Mn | 39.13 Mn | - | -212.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -212.92% |
| Mar 31, 2026 | -179.75% |
| Dec 31, 2025 | -112.92% |
| Sep 30, 2025 | -86.52% |
| Jun 30, 2025 | -64.12% |
| Mar 31, 2025 | -94.43% |
| Dec 31, 2024 | -154.99% |
| Sep 30, 2024 | -121.79% |
| Jun 30, 2024 | -98.67% |
| Mar 31, 2024 | -71.38% |
| Dec 31, 2023 | -92.98% |
| Sep 30, 2023 | -115.35% |
| Jun 30, 2023 | -97.67% |
| Mar 31, 2023 | -80.97% |
| Dec 31, 2022 | -79.82% |
| Sep 30, 2022 | -79.05% |
| Jun 30, 2022 | -77.02% |
| Mar 31, 2022 | -74.98% |
| Dec 31, 2021 | -61.03% |
| Sep 30, 2021 | -61.50% |